Amgen's Q3 earnings call revealed a strong quarter with 10% revenue growth, driven by the continued strength of its Enbrel franchise, as well as growth from other key products such as Prolia and XGEVA. The company also updated its full-year guidance, increasing its revenue and adjusted EPS estimates. Management's tone was optimistic, highlighting the company's pipeline progress, including promising data from its PCSK9 inhibitor, AMG 145, and romosozumab (AMG 785) for osteoporosis. Overall, the call suggests a positive outlook for the company, with management confident in its ability to drive growth and deliver value to shareholders.

[2]